Author

M. Kuljanin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 3 Assay:proteomics· 3 Approach:statistical model· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

J. D. Mancias· 4 shared A. Robichaud· 2 shared B. K. A. Seong· 2 shared K. Stegmaier· 2 shared N. S. Gray· 2 shared A. Conway· 1 shared A. Gikandi· 1 shared A. J. Aguirre· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. D. Mancias

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Covalent Disruptor of YAP-TEAD Association Suppresses Defective Hippo Signaling

M. Fan, W. Lu, J. Che, N. P. Kwiatkowski, Y. Gao, H.-S. Seo, S. B. Ficarro, P. C. Gokhale, Y. Liu, E. A. Geffken, J. Lakhani, K. Song, M. Kuljanin, W. Ji, J. Jiang, , N. Gray

This paper develops a covalent inhibitor of the YAP-TEAD complex, demonstrating its ability to suppress Hippo signaling defects and inhibit cancer cell growth.

bioRxiv · May 10, 2022Cancer Biology

An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML

S. Lin, C. Larrue, B. K. A. Seong, N. V. Dharia, M. Kuljanin, C. Wechsler, G. Kugener, A. Robichaud, A. Conway, T. N. Mashaka, S. Mouche, B. Adane, J. Ryan, J. D. Mancias, S. T. Younger, , K. Stegmaier

This study identifies novel therapeutic targets for AML using an in vivo CRISPR screening platform, revealing SLC5A3 as a metabolic vulnerability and MARCH5 as an apoptosis regulator.

bioRxiv · Dec 28, 2020Cancer Biology

Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules

B. Nabet, F. M. Ferguson, B. K. A. Seong, M. Kuljanin, A. L. Leggett, M. L. Mohardt, A. Robichaud, A. S. Conway, D. L. Buckley, J. D. Mancias, J. E. Bradner, K. Stegmaier, N. S. Gray

This paper introduces dTAGV-1, a VHL-recruiting dTAG molecule that rapidly degrades FKBP12F36V-tagged proteins, overcoming limitations of CRBN-recruiting dTAGs and enabling combination degrader studies in cells and mice.

bioRxiv · Mar 13, 2020Cancer Biology

Defining and targeting adaptations to oncogenic KRASG12C inhibition using quantitative temporal proteomics

N. Santana-Codina, A. S. Chandhoke, Q. Yu, B. Małachowska, M. Kuljanin, A. Gikandi, M. Stanczak, S. Gableske, M. P. Jedrychowski, D. A. Scott, A. J. Aguirre, W. Fendler, N. S. Gray, J. D. Mancias

This study uses quantitative temporal proteomics to analyze KRASG12C inhibitor responses in cancer models, identifying effective drug combinations to overcome resistance.

bioRxiv · Sep 14, 2019Cancer Biology